Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02639910
Title Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MorphoSys AG
Indications

chronic lymphocytic leukemia

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Tafasitamab-cxix + Venetoclax

Idelalisib + Tafasitamab-cxix

Age Groups: senior | adult
Covered Countries USA | ITA | DEU | AUT


No variant requirements are available.